# T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

> **NCT05756556** · PHASE2 · SUSPENDED · sponsor: **ImmVira Pharma Co. Ltd** · enrollment: 68 (estimated)

## Conditions studied

- Melanoma
- Malignant Melanoma

## Interventions

- **COMBINATION_PRODUCT:** T3011 + Cobimetinib

## Key facts

- **NCT ID:** NCT05756556
- **Lead sponsor:** ImmVira Pharma Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-06-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-01
- **Target enrollment:** 68 (ESTIMATED)
- **Why stopped:** Change in drug development and lifecycle management and decide to suspend this study
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05756556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05756556, "T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05756556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*